Sarah S. Mougalian, MD:Neoadjuvant chemotherapy for triple-negative breast cancer is being used more and more commonly. Traditionally, the use of neoadjuvant therapy was limited to breast cancers that were not surgically resectable. However, more and more research has been done in this setting, and more and more providers are using neoadjuvant chemotherapy to try to get patients to breast conservation. There are a number of additional benefits of the use of neoadjuvant chemotherapy, particularly in triple-negative breast cancer.
First, it gives us a glimpse into the activity of the agents being used. For example, if a patient has a palpable breast mass that shrinks in size, presumably that affect is also taking place on any micrometastatic disease. Secondly, we know that prognosis is largely dependent on the pathologic response to treatment. Patients who have a complete pathologic response after neoadjuvant chemotherapy have excellent long-term outcomes. Finally, we know that patients who do have residual disease after neoadjuvant chemotherapy may benefit from the addition of adjuvant therapyfor example, the use of capecitabine as per the CREATE-X clinical trial.
The use of neoadjuvant chemotherapy also affords us a couple of additional benefits. It’s an optimal setting for studying novel agents, novel combinations of agents, with the use of pathologic response as an outcome. And also, it allows us to select for the most high-risk patients for the study of adjuvant therapies in patients who have had neoadjuvant chemotherapy and have residual disease at the time of surgery.
Outside of clinical trials, the standard of care for the treatment of triple-negative breast cancer includes an anthracycline and a taxane. The role of platinum agents is not well-defined at this point. However, there are 2 large randomized clinical trialsCALGB 40603 and GeparSixto—both of which studied the addition of carboplatin to standard chemotherapy in the neoadjuvant setting. In both studies, the combination of chemotherapy with a platinum resulted in higher pathologic complete response rates.
The use of platinum in the adjuvant setting is actively under investigation with the NRG-BR003 study, which is examining the addition of carboplatin to standard third-generation chemotherapy; and in EA1131, which is examining carboplatin versus capecitabine in the adjuvant setting for women who have residual disease after neoadjuvant chemotherapy.
In my practice, I reserve the use of carboplatin, or a platinum agent to the neoadjuvant setting in those patients who are at highest risk of recurrence.
Transcript edited for clarity.
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Survival and Safety Outcomes Factor into Use of Sacituzumab Govitecan in HR+ Breast Cancer
March 29th 2024During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan in hormone receptor–positive breast cancer in the first article of a 2-part series.
Read More